809 related articles for article (PubMed ID: 32641091)
21. Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
Olagunju A; Fowotade A; Olagunoye A; Ojo TO; Adefuye BO; Fagbamigbe AF; Adebiyi AO; Olagunju OI; Ladipo OT; Akinloye A; Adeagbo BA; Onayade A; Bolaji OO; Happi C; Rannard S; Owen A
Trials; 2021 Jan; 22(1):3. PubMed ID: 33397457
[TBL] [Abstract][Full Text] [Related]
22. [Chloroquine as a possible treatment for COVID-19].
Coumou J; de Vries PJ
Ned Tijdschr Geneeskd; 2020 Mar; 164():. PubMed ID: 32391999
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol.
Zeng YM; Xu XL; He XQ; Tang SQ; Li Y; Huang YQ; Harypursat V; Chen YK
Chin Med J (Engl); 2020 May; 133(9):1132-1134. PubMed ID: 32149772
[No Abstract] [Full Text] [Related]
24. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
25. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
Li J; Zhang C; Wu Z; Wang G; Zhao H
Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
Liu W; Zhou P; Chen K; Ye Z; Liu F; Li X; He N; Wu Z; Zhang Q; Gong X; Tang Q; Du X; Ying Y; Xu X; Zhang Y; Liu J; Li Y; Shen N; Couban RJ; Ibrahim QI; Guyatt G; Zhai S
CMAJ; 2020 Jul; 192(27):E734-E744. PubMed ID: 32493740
[TBL] [Abstract][Full Text] [Related]
27. [Adverse effects of lopinavir/ritonavir in critically ill patients with COVID-19].
Vecchio G; Zapico V; Catanzariti A; Carboni Bisso I; Las Heras M
Medicina (B Aires); 2020; 80(5):439-441. PubMed ID: 33048786
[TBL] [Abstract][Full Text] [Related]
28. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.
Cheng CY; Lee YL; Chen CP; Lin YC; Liu CE; Liao CH; Cheng SH
J Microbiol Immunol Infect; 2020 Jun; 53(3):488-492. PubMed ID: 32331982
[TBL] [Abstract][Full Text] [Related]
29. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Hosseini FS; Malektojari A; Ghazizadeh S; Hassaniazad M; Davoodian P; Dadvand H; Nikpoor AR; Nikoofal-Sahlabadi S; Kahoori S; Sepandi M; Hassanipour S; Fathalipour M
Trials; 2021 Jan; 22(1):4. PubMed ID: 33397429
[TBL] [Abstract][Full Text] [Related]
30. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial.
Liu P; Huang Z; Yin M; Liu C; Chen X; Pan P; Kuang Y
Trials; 2020 Dec; 21(1):999. PubMed ID: 33276811
[TBL] [Abstract][Full Text] [Related]
32. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19.
Zhu Z; Lu Z; Xu T; Chen C; Yang G; Zha T; Lu J; Xue Y
J Infect; 2020 Jul; 81(1):e21-e23. PubMed ID: 32283143
[TBL] [Abstract][Full Text] [Related]
33. Does lopinavir measure up in the treatment of COVID-19?
Doggrell SA
Expert Opin Investig Drugs; 2020 Aug; 29(8):793-796. PubMed ID: 32475183
[TBL] [Abstract][Full Text] [Related]
34. [Drug interaction monitoring of lopinavir/ritonavir in COVID-19 patients with cancer].
Zheng XW; Tao G; Zhang YW; Yang GN; Huang P
Zhonghua Nei Ke Za Zhi; 2020 May; 59(5):400-404. PubMed ID: 32114746
[TBL] [Abstract][Full Text] [Related]
35. Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial.
Dastan F; Nadji SA; Saffaei A; Marjani M; Moniri A; Jamaati H; Hashemian SM; Baghaei P; Abedini A; Varahram M; Yousefian S; Tabarsi P
Int Immunopharmacol; 2020 Aug; 85():106688. PubMed ID: 32544867
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trial.
Smit M; Marinosci A; Nicoletti GJ; Perneger T; Ragozzino S; Andrey DO; Stoeckle M; Jacquerioz F; Lebowitz D; Agoritsas T; Meyer B; Spechbach H; Salamun J; Back M; Schaubhut C; Fuchs S; Decosterd L; Battegay M; Guessous I; Chappuis F; Kaiser L; Labhardt ND; Calmy A
BMJ Open; 2020 Nov; 10(11):e040110. PubMed ID: 33184083
[TBL] [Abstract][Full Text] [Related]
37. BET 1: Lopinavir-ritonavir and COVID-19.
Dolan D; Ingham J; Baombe J
Emerg Med J; 2020 Jul; 37(7):450-451. PubMed ID: 32616658
[No Abstract] [Full Text] [Related]
38. Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia.
Beyls C; Martin N; Hermida A; Abou-Arab O; Mahjoub Y
Circ Arrhythm Electrophysiol; 2020 Aug; 13(8):e008798. PubMed ID: 32809882
[No Abstract] [Full Text] [Related]
39. Ritonavir- and lopinavir-induced eryptosis in a SARS-CoV-2-infected patient.
Stalder G; Alberio L
Blood; 2020 Aug; 136(7):915. PubMed ID: 32790855
[No Abstract] [Full Text] [Related]
40. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
Takayama S; Namiki T; Ito T; Arita R; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Kainuma M; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T
Trials; 2020 Oct; 21(1):827. PubMed ID: 33008479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
